Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa

Background Chemoimmunotherapy is the first-line therapy for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and is currently the main induction treatment option for patients with locoregionally advanced NPC. However, it remains unclear whether combining immunotherapy with standa...

Full description

Bibliographic Details

Published in:	Annals of Medicine
Main Authors:	Kun-Peng Wu, Qing-Qing Li, Xu-Qiang Luo, Xiao-Xi Wang, Yan-Zhen Lai, Dan Tian, Hong-cheng Yang, Xue-Ling Wei, Lan-Ying Wang, Qiu-Ming Li, Dao Zhu, Si-Jie Chen, Yang-Si Li
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	Induction treatment immunotherapy chemotherapy chemoimmunotherapy nasopharyngeal carcinoma
Online Access:	https://www.tandfonline.com/doi/10.1080/07853890.2025.2453091